Tumor necrosis factor receptor superfamily member 17 ( TNFRSF 17) , also known as B cell maturation antigen ( BCMA ) or CD 269 antigen, is one of the members of the tumor necrosis factor receptor superfamily. This receptor is preferentially expressed in mature B lymphocytes and is involved in B cell development and autoimmune response. This receptor has been shown to specifically bind to tumor necrosis factor (ligand) superfamily member 13B (TNFSF13BABAFF) , and cause NF- kappa B and MAPK8/JNK activation. BCMA also binds to different members of the TRAF family to mediate the transmission of cell survival and proliferation signals, so it can be used as a molecular target for drug development for certain immunodeficiency or autoimmune diseases. In BCMA as a target CAR-T has been in clinical trials for multiple myeloma. This product is a BCMA-FC recombinant protein (FC tag can be removed by enterokinase), which can be used for monoclonal antibody screening or antibody function verification.
Product name: Recombinant human BCMA protein
Species: Human origin
Gene sequence number: NP_001183.2
Tags: Human-Fc Tag
Tag site: N- terminal
Restriction site: enterokinase
Expression area: extracellular segment ( 1-54AA )
Host cell: 293F
Purification method: Protein A column
Preservation system: PBS+20% glycerol
Storage conditions: -80℃
Illustration: Lane M on the left is protein MW marker, Lane 1 is 10ug BCMA-Fc protein;
The image on the right shows the FACS detection of the binding of BCMA protein to 293T overexpressing anti-BCMA-CAR.